NCT01973062 · OUTCOME

Overall Survival

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma · Source last updated 2020-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 2 years

What was measured

The number of patients alive up to two years after treatment

Analysis population: Only one patient registered. No patient data analyzed

Groups in this outcome

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan

Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

description

The number of patients alive up to two years after treatment

groups

description
Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
id
OG000
title
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan

population Description

Only one patient registered. No patient data analyzed

reporting Status

POSTED

time Frame

Up to 2 years

title

Overall Survival

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice